Cytek Biosciences (NASDAQ:CTKB – Get Free Report) is expected to release its earnings data after the market closes on Wednesday, March 12th. Analysts expect Cytek Biosciences to post earnings of $0.06 per share and revenue of $59.38 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Cytek Biosciences Price Performance
Shares of NASDAQ:CTKB opened at $4.31 on Wednesday. Cytek Biosciences has a 12 month low of $4.20 and a 12 month high of $8.44. The firm has a market capitalization of $555.18 million, a P/E ratio of -53.87 and a beta of 1.40. The company’s fifty day moving average price is $5.74 and its 200 day moving average price is $5.74.
Cytek Biosciences announced that its Board of Directors has authorized a stock buyback plan on Monday, December 30th that permits the company to repurchase $50.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 5.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Cytek Biosciences
About Cytek Biosciences
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
- Five stocks we like better than Cytek Biosciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Expert Stock Trading Psychology Tips
- Tesla Stock: Finding a Bottom May Take Time
- The Role Economic Reports Play in a Successful Investment Strategy
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.